Required fields are marked with *

Verification code

Deferiprone

{PARAM:[Name]}({[CAS]})
Category Hepatitis C Virus (HCV)
CAS 30652-11-0
Description A chelator that could replace disferrioxamine. It is orally and parenterally effective in the removal of iron in vivo from rabbits and mice and also from transferrin and ferritin in vitro.
Quotation Now

Product Information

Synonyms 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone; 1,2-Dimethyl-3-hydroxy-4-pyridone; CP 20
IUPAC Name 3-hydroxy-1,2-dimethylpyridin-4-one
Molecular Weight 139.15
Molecular Formula C7H9NO2
Canonical SMILES CC1=C(C(=O)C=CN1C)O
InChI InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3
InChIKey TZXKOCQBRNJULO-UHFFFAOYSA-N
Boiling Point 232.7 °C at 760 mmHg
Melting Point 272-275 °C(lit.)
Flash Point 94.5±27.3 °C
Purity 99 %
Density 1.225 g/cm3
Solubility In Vitro:
DMSO : 7.14 mg/mL(51.31 mM;Need ultrasonic)
H2O : 3.33 mg/mL(23.93 mM;Need ultrasonic)
In Vivo:
1.Add each solvent one by one:PBS
Solubility: 10 mg/mL (71.86 mM); Clear solution; Need ultrasonic
2.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline
Solubility: ≥ 0.71 mg/mL (5.10 mM); Clear solution
3.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline)
Solubility: ≥ 0.71 mg/mL (5.10 mM); Clear solution
4.Add each solvent one by one:10% DMSO >> 90%corn oil
Solubility: ≥ 0.71 mg/mL (5.10 mM); Clear solution
Appearance White to off-white (Solid)
Storage Powder: -20°C: 3 years; 4°C: 2 years; In solvent: -80°C: 6 months; -20°C: 1 month
Complexity 228
Exact Mass 139.063328530
Index Of Refraction 1.565
In Vitro Deferiprone (100 μM) protects muscle cells with doxorubicin-induced release of Lactate dehydrogenase. Deferiprone (300 μM) quickly and efficiently removes ferric ions (III) from doxorubicin complexes. Deferiprone (300 μM) rapidly enters myocytes and displaces iron ions from the intracellular iron-calcein complex captured by fluorescence quenching, indicating that in myocytes, deferiprone should also be able to replace iron ions in its doxorubicin complex. In the xanthine oxidase/xanthine superoxide generation system, Deferiprone (3 mM) is also able to greatly reduce the hydroxyl radical production of the iron ion(III)-doxorubicin complex. Deferiprone (0.5 mM) increases the clearance of free iron from RBC membranes in a time-dose-dependent manner.Deferiprone (0.3 mM) effectively inhibits the transfer of radioactive iron from iron-loaded heart cells and protects or restores mitochondrial respiratory enzyme activity. In iron-loaded heart cells, Deferiprone (1 mM) leads to a sharp decrease in complex I-III activity. Deferiprone exhibited cytotoxic effects on human tumor cell lines HSC-2, HSC-3 and HL-60 with IC50s of 13.5 μg/ml, 9.9 μg/ml and 10.6 μg/ml, and HK1 cytotoxicity to HL-60 and HSC-2 cells was reduced inthe presence of FeCl3. Deferiprone (100 μg/ml) induces internucleosome DNA disruption in HL-60 cells, but adds FeCl3 to inhibit DNA disruption. Deferiprone (100 μg/ml) activates Caspase 3, 8, and 9 in HSC-2 cells.
In Vivo In rabbits, Deferiprone (100 mg/kg) reduced mean basilar artery cross-sectional area by 24%. In rabbits, Deferiprone (100 mg/kg) combined with subarachnoid hemorrhage (SAH) exhibits a variable number of endoelastic membrane folds.
PSA 42.23000
Target HCV; Ferroptosis
Vapor Pressure 0.0±1.0 mmHg at 25°C
XLogP3-AA 0.5

TAKE YOUR NEXT STEPS

Get Started With Our Industry Experience And Client-Centric Focus!

Talk to Us

Copyright © 2025 BOC Sciences. All rights reserved.